Literature DB >> 35478142

Antihypertensive Drug Combinations Modify Cisplatin-induced Acute Kidney Injury.

Koji Takeuchi1, Rintaro Sogawa1, Satoko Tsuruhashi1, Chika Motooka1, Sakiko Kimura1, Chisato Shimanoe1.   

Abstract

BACKGROUND/AIM: There is limited evidence about the nephrotoxicity of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with concomitant cisplatin (CDDP). We investigated whether combinations of antihypertensive drugs are associated with CDDP-related acute kidney injury (AKI) using the Japanese Adverse Drug Event Report database. PATIENTS AND METHODS: We analysed 544,864 reports in the database from 2004 to 2020. A reporting odds ratio (ROR) and confidence interval (CI) with adjustment for potential confounding factors was calculated for AKI for each drug and the combined use of the drugs and CDDP.
RESULTS: CDDP, CCBs, and RAS inhibitors were all detected signals for AKI. The ROR in cases with concomitant use of CCBs, RAS inhibitors, and CDDP (adjusted ROR 7.28; 95% CI=5.56-9.54) was higher than that in cases with use of each drug.
CONCLUSION: AKI may require more attention when patients receiving CDDP take CCBs and RAS inhibitors together.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cisplatin; acute kidney injury; antihypertensive drug

Mesh:

Substances:

Year:  2022        PMID: 35478142      PMCID: PMC9087053          DOI: 10.21873/invivo.12843

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  33 in total

1.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole.

Authors:  E P Van Puijenbroek; A C Egberts; R H Meyboom; H G Leufkens
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  The influence of verapamil on renal function in patients treated with cisplatin.

Authors:  J J Offerman; S Meijer; D T Sleijfer; N H Mulder; A J Donker; H Schraffordt Koops; G K van der Hem
Journal:  Clin Nephrol       Date:  1985-11       Impact factor: 0.975

3.  Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.

Authors:  Shunji Endo; Yukinori Kurokawa; Makio Gamoh; Yutaka Kimura; Jin Matsuyama; Hirokazu Taniguchi; Atsushi Takeno; Ryohei Kawabata; Junji Kawada; Toru Masuzawa; Kazuyoshi Yamamoto; Kouji Kobayashi; Daisuke Sakai; Toshio Shimokawa; Taroh Satoh
Journal:  Anticancer Res       Date:  2019-02       Impact factor: 2.480

4.  Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan.

Authors:  Daisuke Sano; Takuo Fujisawa; Motohiko Tokuhisa; Minaki Shimizu; Tomofumi Sakagami; Takashi Hatano; Goshi Nishimura; Yasushi Ichikawa; Hiroshi Iwai; Nobuhiko Oridate
Journal:  Anticancer Res       Date:  2019-12       Impact factor: 2.480

5.  Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.

Authors:  Shveta S Motwani; Gearoid M McMahon; Benjamin D Humphreys; Ann H Partridge; Sushrut S Waikar; Gary C Curhan
Journal:  J Clin Oncol       Date:  2018-01-10       Impact factor: 44.544

6.  Current prescription status of antihypertensive drugs in Japanese patients with hypertension: Analysis by type of comorbidities.

Authors:  Takayuki Ishida; Akinori Oh; Shinzo Hiroi; Yukio Shimasaki; Takuya Tsuchihashi
Journal:  Clin Exp Hypertens       Date:  2018-05-21       Impact factor: 1.749

Review 7.  Treatment of non-small cell lung cancer (NSCLC).

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Efimia Boutsikou; Nikolaos Machairiotis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Ilias Karapantzos; Haidong Huang; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

8.  Risk factors for renal toxicity after inpatient cisplatin administration.

Authors:  Elena Galfetti; Alessandra Cerutti; Michele Ghielmini; Emanuele Zucca; Luciano Wannesson
Journal:  BMC Pharmacol Toxicol       Date:  2020-03-02       Impact factor: 2.483

9.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database.

Authors:  Junko Abe; Ryogo Umetsu; Kanako Mataki; Yamato Kato; Natsumi Ueda; Yoko Nakayama; Yuuki Hane; Toshinobu Matsui; Haruna Hatahira; Sayaka Sasaoka; Yumi Motooka; Hideaki Hara; Zenichiro Kato; Yasutomi Kinosada; Naoki Inagaki; Mitsuhiro Nakamura
Journal:  J Pharm Health Care Sci       Date:  2016-06-21

10.  The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly.

Authors:  Jie-Qiong Liu; Guang-Yan Cai; Si-Yang Wang; Yu-Huan Song; Yuan-Yuan Xia; Shuang Liang; Wen-Ling Wang; Sa-Sa Nie; Zhe Feng; Xiang-Mei Chen
Journal:  Ther Clin Risk Manag       Date:  2018-07-25       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.